Plain-English translation of NCT07440290 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
The DETERMINE trial is testing combined with — two medications that target cancer cells with a specific genetic mutation called BRAF V600. This combination is being studied in people of all ages (children, teenagers, and adults) who have rare cancers or uncommon types of more common cancers that carry this genetic change. The goal is to see if this medication combination can help control these cancers and potentially offer new treatment options through the NHS.
Many rare cancers or unusual forms of common cancers are hard to treat because there aren't enough treatment options designed specifically for them. This trial exists to find out whether this medication can work for people whose cancers have this particular genetic mutation, even if their cancer type is uncommon.
You likely qualify if…
You likely don't qualify if…
If you join, you'll start by having a biopsy (a small tissue sample) taken and blood tests performed. Then you'll take the medication combination as a pill at home, continuing until your cancer stops responding, you experience unacceptable side effects, or you decide to stop. You'll have regular blood tests and hospital visits throughout your treatment, and after you finish the medication, you'll have follow-up appointments every 3 months for 2 years to monitor how you're doing.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
United Kingdom